The cardiovascular benefits of SGLT2 inhibitors, particularly empagliflozin, are evident in patients with and without diabetes [24], regardless of whether their LVEF is reduced or preserved [25,26]. This evidence concerns the gene SLC5A2 and diabetes mellitus.